Paweł Trawkowski jest absolwentem Wydzialu Marketingu i Zarzadzania Uniwestytetu Warszawskiego z 25-letnim doświadczeniem menadżerskim i szeroką wiedza nabyta w największych, międzynarodowych firmach farmaceutycznych. Od 1997 do 2003 roku pracowal w firmie Abbott Laboratories Poland, na stanowisku
Read moreFollows an ongoing strategic portfolio review by partner Galapagos Molecure to regain all rights, associated data, IP and inventory to OATD-01 Evaluating potential first indication and development plan for the asset in sarcoidosis Warsaw, Poland June
Read moreMolecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of
Read morePeople are the foundation of Molecure and they are the creators of the best ideas generated in our laboratories. We work together as a team to discover therapies for the previously incurable diseases. It is this
Read moreMolecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of
Read moreMarcin ma ponad 15 lat doświadczenia w zarządzaniu projektami badawczymi i inwestycyjnymi w branży biotechnologicznej oraz diagnostyki medycznej (ang. Life Science). Łącznie prowadził ponad 40 projektów B+R o łącznym budżecie ponad 200 mln euro. Współtworzył lub
Read moreMarta Dudek, MD, PhD, received her PhD degree in biochemistry from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences, in collaboration with the University of Warsaw in 2012. She has worked with oncological patients
Read moreDr. Samson Fung graduated from the University of Freiburg, Germany and obtained his board certification in internal medicine with sub-specialization in oncology and hematology. Dr. Fung brings more than three decades of global industry and senior
Read moreDr van der Horst has a strong track record of biotech business development having acted as lead negotiator in over 20 licensing and M&A transactions and raised over $1.3 billion through capital market transactions during his
Read more
